» Articles » PMID: 11102316

Bruton Tyrosine Kinase (BTK) in X-linked Agammaglobulinemia (XLA)

Overview
Journal Front Biosci
Specialty Biology
Date 2000 Dec 5
PMID 11102316
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

X-linked agammaglobulinemia (XLA) is a heritable immunodeficiency disorder that is caused by a differentiation block leading to almost complete absence of B lymphocytes and plasma cells. The affected protein is a cytoplasmic protein tyrosine kinase, Bruton's agammaglobulinemia tyrosine kinase (Btk). Btk along with Tec, Itk, Bmx and Txk belong to a distinct family of protein kinases. These proteins contain five regions; PH, TH, SH3, SH2 and kinase domains. Mutations causing XLA may affect any of these domains. About 380 unique mutations have been identified and are collected in a mutation database, BTKbase. Here, we describe the structure, function, and interactions of the affected signaling molecules in atomic detail.

Citing Articles

In vivo Bruton's tyrosine kinase inhibition attenuates alcohol-associated liver disease by regulating CD84-mediated granulopoiesis.

Thevkar Nagesh P, Cho Y, Zhuang Y, Babuta M, Ortega-Ribera M, Joshi R Sci Transl Med. 2024; 16(759):eadg1915.

PMID: 39110779 PMC: 11831603. DOI: 10.1126/scitranslmed.adg1915.


Severe Tick-Borne Encephalitis (TBE) in a Patient with X-Linked Agammaglobulinemia; Treatment with TBE Virus IgG Positive Plasma, Clinical Outcome and T Cell Responses.

Hedin W, Bergman P, Akhirunessa M, Soderholm S, Buggert M, Granberg T J Clin Immunol. 2024; 44(5):116.

PMID: 38676861 PMC: 11055791. DOI: 10.1007/s10875-024-01718-5.


Clinical features and mutational analysis of X-linked agammaglobulinemia patients in Malaysia.

Chear C, Ismail I, Chan K, Mohd Noh L, Kassim A, Abdul Latiff A Front Immunol. 2023; 14:1252765.

PMID: 37809070 PMC: 10560089. DOI: 10.3389/fimmu.2023.1252765.


Systematic simulation of the interactions of pleckstrin homology domains with membranes.

Le Huray K, Wang H, Sobott F, Kalli A Sci Adv. 2022; 8(27):eabn6992.

PMID: 35857458 PMC: 9258823. DOI: 10.1126/sciadv.abn6992.


The TKI Era in Chronic Leukemias.

De Novellis D, Cacace F, Caprioli V, Wierda W, Mahadeo K, Tambaro F Pharmaceutics. 2021; 13(12).

PMID: 34959482 PMC: 8709313. DOI: 10.3390/pharmaceutics13122201.